Relationship of serum methotrexate concentration in high-dose methotrexate chemotherapy to prognosis and tolerability: A prospective cohort study in chinese adults with osteosarcoma

Current Therapeutic Research - Clinical and Experimental

Volumn 70, Issue 2, 2009, Pages 150-160

  Lin, Feng ^a   Juan, Yue ^a   Zheng, Shui Er ^a   Shen, Zan ^a   Tang, Li Na ^a   Zhao, Hui ^a   Yao, Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

MTX; osteosarcoma; prognosis; serum concentration; side effect

Indexed keywords

CISPLATIN; DOXORUBICIN; FOLINIC ACID; IFOSFAMIDE; MESNA; METHOTREXATE;

ADULT; AGE; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CHINESE; COHORT ANALYSIS; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RASH; SEX DIFFERENCE; SIDE EFFECT;

EID: 65549155327     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2009.04.005     Document Type: Article

References (25)

1. Jaffe N. Osteogenic sarcoma: State of the art with high-dose methotrexate treatment. Clin Orthop Relat Res 120 (1976) 95-102
2. Piekarczyk A., Zimak J., and Taljanski W. Pharmacokinetics of methotrexate and therapeutic drug monitoring in children with osteosarcoma. Computer simulation using a pharmacokinetic model [in Polish]. Med Wieku Rozwoj 4 Suppl 2 (2000) 27-33
3. Dupuis C., Mercier C., Yang Ć., et al. High-dose methotrexate in adults with osteosarcoma: A population pharmacokinetics study and validation of a new limited sampling strategy. Anticancer Drugs 19 (2008) 267-273
4. Enneking W.F. Musculoskeletal tumor staging: 1988 Update. Cancer Treat Res 44 (1989) 39-49
5. Hutchinson T.A., Boyd N.F., Feinstein A.R., et al. Scientific problem in clinical scales, as demonstrated in the Karnofsky index of performance status. J Chronic Dis 32 (1979) 661-666
6. Cui L., He Y.Q., Liu Y.W., et al. Modified HPLC method for determination of methotrexate in human plasma [in Chinese]. Lab Med 21 (2006) 445-448
7. Nirenberg A., Mosende C., Mehta B.M., et al. High-dose methotrexate with citrovorum factor rescue: Predictive value of methotrexate concentrations and corrective measures to avert toxicity. Cancer Treat Rep 61 (1977) 779-783
8. Bacci G., Longhi A., Fagioli F., et al. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 Year experience at Rizzoli Institute, Italy. Eur J Cancer 41 (2005) 2836-2845
9. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
10. Domin B.A., Grill S.P., Bastow K.F., et al. Effect of methotrexate on dihydrofolate reductase activity in methotrexate-resistant human KB cells. Mol Pharmacol 21 (1982) 478-482
11. Umeda T., Takada N., Hodaka E., et al. Evaluation of severe side effects of high-dose methotrexate in osteosarcoma [in Japanese]. Gan to Kagaku Ryoho 11 (1984) 285-294
12. Liu H., Zhang Y., and Kong P.Y. Clinical study of high dose MTX combined with chemotherapy in the treatment of non-Hodgkin's lymphoma [in Chinese]. Chongqing Med 32 (2003) 1298-1299
13. Bacci G., Ferrari S., Delepine N., et al. Predictive factors of histological response to primary chemotherapy in osteosarcoma of the extremity: Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 16 (1998) 658-663
14. Bacci G., Loro L., Longhi A., et al. No correlation between methotrexate serum level and histological response in the pre-operative treatment of extremity osteosarcoma. Anticancer Drugs 17 (2006) 411-415
15. Li Y.M., Zhang W.Q., Qi K.L., et al. The serum MTX concentration determination with different dose of treatment [in Chinese]. Acta Academial Medicinal Primae Shanghai 7 (1978) 407-410
16. Cano J.P., Aubert C., Rigault J.P., et al. Advantages and limitations of pharmacokinetic studies in the rationalization of anticancer therapy: Methotrexate and 5-FU. Cancer Treat Rep 65 Suppl 3 (1981) 33-42
17. Bacci G., Picci P., Ruggieri P., et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 65 (1990) 2539-2553
18. Ferrari S., Sassoli V., Orlandi M., et al. Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. J Chemother 5 (1993) 135-141
19. Graf N., Winkler K., Betlemovic M., et al. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 12 (1994) 1443-1451
20. Delepine N., Delepine G., Cornille H., et al. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res 15 (1995) 489-494
21. Bacci G., Ferrari S., Picci P., et al. Methotrexate serum concentration and histological response to multiagent primary chemotherapy for osteosarcoma of the limbs. J Chemother 8 (1996) 472-478
22. Zelcer S., Kellick M., Wexler L.H., et al. Methotrexate levels and outcome in osteosarcoma. Pediatr Blood Can 4 (2005) 638-642
23. Crews K.R., Liu T., Rodriguez-Galindo C., et al. High dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 100 (2004) 1724-1733
24. Cheng K.K. Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/ vomiting and oral mucositis in children with cancer. Eur J Cancer Care (Engl) 17 (2008) 306-311
25. Bacci G., Ferrari S., Longhi A., et al. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy. Oncol Rep 10 (2003) 851-857